Evidence map›Paper›PMID 36309516›Full record

ArticleNature communications2022

The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors.

Sujun Chen, Jessica Petricca, Wenbin Ye, Jiansheng Guan, Yong Zeng, Nicholas Cheng, Linsey Gong, Shu Yi Shen, Junjie T Hua, Megan Crumbaker and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Epigenetic Instability-Based Metrics in Cell-Free DNA for Early Cancer Detection.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 9 institutions in 4 countries.

Sujun Chen *Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-1941-3951
Jessica Petricca *Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
Wenbin Ye *Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-7811-2710
Jiansheng GuanPrincess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
Yong ZengPrincess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
Nicholas ChengDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Linsey GongPrincess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.ORCID 0000-0003-0400-3180
Shu Yi ShenPrincess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.ORCID 0000-0001-7036-2291
Junjie T HuaDepartment of Radiation Oncology, University of California, San Francisco, CA, USA.
Megan CrumbakerDepartment of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia.
Michael FraserPrincess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
Stanley LiuDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-6851-0857
Scott V BratmanPrincess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.ORCID 0000-0001-8610-4908
Theodorus van der KwastDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-8640-5786
Trevor PughPrincess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-8073-5888
Anthony M JoshuaDepartment of Pharmacology & Toxicology, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-5159-4580
Daniel D De CarvalhoPrincess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
Kim N ChiBritish Columbia Cancer Agency, Vancouver Centre, Vancouver, BC, Canada.
Philip AwadallaOntario Institute for Cancer Research, Toronto, ON, Canada.ORCID 0000-0001-9946-6393
Guoli JiDepartment of Automation, Xiamen University, Xiamen, Fujian, China. glji@xmu.edu.cn.
Felix FengDepartment of Radiation Oncology, University of California, San Francisco, CA, USA. felix.feng@ucsf.edu.ORCID 0000-0002-0963-7687
Alexander W WyattVancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. awwyatt@mail.ubc.ca.ORCID 0000-0003-2399-0329
Housheng Hansen HePrincess Margaret Cancer Center, University Health Network, Toronto, ON, Canada. Hansenhe@uhnresearch.ca.ORCID 0000-0003-2898-3363
University Health Network · CAUniversity of Toronto · CAUniversity of California, San Francisco · USBC Cancer Agency · CAOntario Institute for Cancer Research · CASt Vincent's Hospital Sydney · AUSunnybrook Health Science Centre · CAUniversity of British Columbia · CAXiamen University · CN

Funding

CIHR 181755
6 · The paper itself

Abstract

Metastatic prostate cancer remains a major clinical challenge and metastatic lesions are highly heterogeneous and difficult to biopsy. Liquid biopsy provides opportunities to gain insights into the underlying biology. Here, using the highly sensitive enrichment-based sequencing technology, we provide analysis of 60 and 175 plasma DNA methylomes from patients with localized and metastatic prostate cancer, respectively. We show that the cell-free DNA methylome can capture variations beyond the tumor. A global hypermethylation in metastatic samples is observed, coupled with hypomethylation in the pericentromeric regions. Hypermethylation at the promoter of a glucocorticoid receptor gene NR3C1 is associated with a decreased immune signature. The cell-free DNA methylome is reflective of clinical outcomes and can distinguish different disease types with 0.989 prediction accuracy. Finally, we show the ability of predicting copy number alterations from the data, providing opportunities for joint genetic and epigenetic analysis on limited biological samples.

Indexed as

Cell-Free Nucleic AcidsProstatic NeoplasmsDNA MethylationEpigenomeHumansMaleProstateCell-Free Nucleic Acids

Identifiers

PMID36309516
PMCPMC9617856
OpenAlexW4307848212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.